Applications of N-(2,4-Dinitrophenyl)-L-Valine in Industrial Manufacturing

N-(2,4-Dinitrophenyl)-L-Valine serves as a specialized chemical intermediate in precise industrial synthesis processes for pharmaceuticals, peptide modification, analytical chemistry, and advanced research. As the direct manufacturer, we supply this material to qualified downstream plants with thorough documentation to support regulated and custom synthesis demands.

1. Peptide Sequence Analysis and Synthesis

Analytical and peptide contract manufacturers use N-(2,4-Dinitrophenyl)-L-Valine extensively for N-terminal modification and identification during stepwise peptide analysis. It participates in Edman degradation and alternate sequencing protocols, providing stable, chromophore-labeled amino acid derivatives for high-confidence detection by HPLC and UV methods. Material entry point is the selective derivatization during sample prep, contributing to reproducible chromatogram profiles for pharmaceutical QC or research sequence validation. Strict process control ensures minimal side reactions and high-purity output for reliable downstream data generation.

Industry compliance standards

• USP General Chapter <825> Related Techniques
• ICH Q6A Specifications: Test Procedures and Acceptance Criteria for New Drugs
• ISO 17025 Analytical Laboratory Accreditation
• FDA 21 CFR Part 211 (cGMP, US finished pharmaceuticals)

Typical usage ratio

• 1.0–1.5 molar equivalents for free amino group derivatization; ratio adjusted based on peptide length and environmental pH during reaction

Downstream process integration

• Single-step derivatization prior to peptide release or sequencing analysis
• Automated batch or microvolume manual derivatization in research labs
• Direct addition to oligopeptide solutions at controlled room temperature
• Waste neutralization with sodium carbonate for chromatographic sample prep

Final product types

• Protein sequence chromatogram reports
• Derivatized peptide reference standards
• Custom peptide mapping panels
• Pharmacopoeial reference substances for QC

2. Chiral Synthesis of APIs and Intermediates

Specialty pharmaceutical plants use this material for the chiral derivatization and protection of amino groups in the multi-step synthesis of key active pharmaceutical ingredients. Its stable aromatic group facilitates selective separation of L-valine configured intermediates by crystallization or preparative chromatography. Site-specific addition occurs during solid-phase or solution-phase coupling protocols, ensuring high stereochemical purity demanded by global drug master files. Release testing verifies residual protection group and final intermediate yield before API assembly.

Industry compliance standards

• EMA Guideline on Specifications: Chemical APIs (CHMP/QWP/130/96)
• JP XV (Japanese Pharmacopoeia) requirements for intermediate isolation
• US FDA DMF (Type II) documentation
• ICH Q7A GMP for Active Pharmaceutical Ingredients

Typical usage ratio

• 0.95–1.05 molar equivalents per target amine function, adjusted according to batch reaction scale and stepwise conversion yield

Downstream process integration

• Addition to protected amino acids during coupling reaction
• Removal in final deprotection step before target active formation
• Solvent selection optimized for polar or non-polar compatibility
• Inline HPLC and NMR tracking of protection group conversion

Final product types

• Single-enantiomer pharmaceutical intermediates
• Labeled chiral crystals for further synthesis
• Peptidomimetic API building blocks
• DMF-listed starting materials

3. Analytical Reference Standard Production

Specialty analytical laboratories and certified reference material producers employ N-(2,4-Dinitrophenyl)-L-Valine as a core starting material to generate calibration standards for amino acid detection. Chemical purity and absolute configuration are validated per compendial methods. Installation in vertical standards production processes under ISO and pharmacopeial scrutiny guarantees batch-to-batch consistency. These standards directly calibrate LC-MS and GC-MS systems, supporting regulated release testing for pharma, biotech, and food industries.

Industry compliance standards

• ISO 17034 General Requirements for Reference Material Producers
• USP Reference Standards program
• EP General Chapter 2.2.46 (Chromatographic Separation Techniques)
• FDA 21 CFR Part 211.194 (Laboratory Controls)

Typical usage ratio

• 100% loading as neat standard or 10–100 μg/mL in acetonitrile matrix for prep; determined by instrument sensitivity and calibration range

Downstream process integration

• Dissolution into calibration ampoules in controlled environment
• Packaging as powder or solution in amber vials
• Stability evaluation under USP and EP protocols
• Assignment of certificate of analysis with exact purity and traceability

Final product types

• Amino acid HPLC/UV calibration standards
• Mass spectrometry working standards
• Secondary reference substances for method validation
• Research kit components for international QC labs

4. Custom Derivatization in Research and Diagnostics

Biotech research institutes and diagnostics kit manufacturers source this compound for site-specific amino acid labeling in advanced molecular biology workflows. Its dual nitro-substituted phenyl ring supports high-contrast detection when conjugated to peptides or oligonucleotides, streamlining structural elucidation and high-throughput screening. Researchers customize its use for fluorescence quenching, radiolabeling, or probe generation. Entry into synthesis protocols occurs via direct addition to amino acid mixtures or solid supports, with careful stoichiometry to minimize excess.

Industry compliance standards

• ISO 13485:2016 for medical device and diagnostics kit production
• GLP (Good Laboratory Practice) for research workflows
• NIH Recombinant DNA Guidelines (for probe applications)
• OECD Principles of Good Laboratory Practice

Typical usage ratio

• 0.5–2.0 molar equivalents, selected based on labeling density, conjugation protocol, and target macromolecule accessibility

Downstream process integration

• Direct addition to oligonucleotide or peptide solution during probe synthesis
• Chromatographic purification for excess group removal
• Integration into microplate or slide-based assay prep
• Co-labeling step for multi-analyte detection kits

Final product types

• Labeled diagnostic probes
• Research use-only conjugates
• Oligonucleotide-based array standards
• Custom modified amino acids for structural biochemistry